NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-25-026 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Funding Opportunity PAR-25-025 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO which utilizes an R61/R33 phased approach.
Funding Opportunity PAR-25-239 from the NIH Guide for Grants and Contracts. This purpose of this NOFO is to support, through the cooperative agreement mechanism, investigator-initiated observational studies or biomarker validation studies that require prospective collection of data/biospecimens or continued analysis of data/biospecimens collected as part of a previous NIDCR cooperative agreement.
Notice NOT-AG-24-088 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-25-299 from the NIH Guide for Grants and Contracts. This initiative will support multi-level and/or multi-domain intervention research to reduce disparities in liver diseases and liver cancer among populations who experience health disparities in the United States (U.S.). This NOFO is being reissued in accordance with the simplified review criteria in effect for application due dates after January 25, 2025.
Funding Opportunity RFA-HD-26-005 from the NIH Guide for Grants and Contracts. This funding opportunity seeks applications to support national programs of mentored career development and training in research for junior faculty in clinical rehabilitation fields. The goal is to attract and nurture a new and geographically-diverse cadre of clinically trained rehabilitation researchers and support their transition to independent funding. The program should support scholars with a clinical background in medical rehabilitation (e.g., physiatry, physical/occupational therapy and allied health).
Funding Opportunity RFA-OD-25-001 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to invite R01 applications to support new high-priority biomedical and behavioral research that will provide scientific data to inform the regulation of tobacco products to protect public health. Research Projects must address the current high-priority research topics related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this NOFO will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this NOFO are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Notice NOT-DA-24-061 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-25-297 from the NIH Guide for Grants and Contracts. The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.
Funding Opportunity PAR-25-242 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. Applicants are required to propose partnerships between at least one U.S. institution and one LMIC institution.
Notice NOT-EY-25-001 from the NIH Guide for Grants and Contracts
Notice NOT-MD-25-006 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-25-310 from the NIH Guide for Grants and Contracts. This NOFO is a call to action in response to the mental health crisis in the United States. We seek applications that will study methods to increase access to evidence-based interventions and services for youth mental health, including those living in rural areas, inner cities, and other under-resourced areas, and youth experiencing housing and food insecurities and out-right homelessness. Applications should address research related to optimizing assessment, intervention and service strategies, overcoming challenges related to the workforce shortage, wait lists for treatment, integration of treatment and preventive interventions into settings where people are most likely to be best identified as needing care (eg: schools, social service, pediatric medicine and justice), and service interventions that address systemic barriers to access and quality of mental health care (structural, policy, organizational, value (cost/financing), management).
Notice NOT-AI-25-002 from the NIH Guide for Grants and Contracts
Notice NOT-AI-24-085 from the NIH Guide for Grants and Contracts
Notice NOT-OD-25-041 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-25-251 from the NIH Guide for Grants and Contracts. The purpose of the NIAID Career Transition Award program is to assist postdoctoral fellows' transition to positions of assistant professor or equivalent and initiate a successful biomedical career as an independent research scientist.
Funding Opportunity RFA-RM-24-012 from the NIH Guide for Grants and Contracts. The purpose of the Advancing Non-Invasive Optical Imaging Approaches for Biological Systems initiative is to overcome the problem of light scattering in biological systems. Current optical imaging techniques that are non-invasive and allow rapid assessment of tissue function and structure suffer from strong light scattering within biological tissues, limiting the penetration depth and resolution. This funding opportunity encourages development of next-generation non-invasive or minimally-invasive optical imaging techniques to overcome these issues and to allow deeper imaging of biological systems with high spatial and temporal resolution.
Funding Opportunity PAR-25-215 from the NIH Guide for Grants and Contracts. The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.
Funding Opportunity PAR-25-216 from the NIH Guide for Grants and Contracts. The objective of the NIH Career Transition Award (K22) is to provide support to outstanding basic or clinical investigators to develop their independent research skills through a two phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. This NINDS K22 is specifically designed to facilitate the transition of NINDS intramural neurologist- and neurosurgeon-scientists to independent, academic faculty positions that support clinician-scientists to engage in independently funded scientific research as well as clinical activities.